Background/aims Topical agents to lower intraocular pressure (IOP) are the most common initial therapeutic measure in glaucoma prevention. This study aims to assess treatment success duration among patients initiating or intensifying topical glaucoma medication. Methods Medical records (2013‒2018) for adults initiating/intensifying topical glaucoma medication were extracted from five secondary-care and tertiary-care UK ophthalmology centres. Main study outcomes were time from treatment initiation/intensification to treatment failure (<20% IOP reduction or IOP >21 mm Hg at consecutive clinic visits, or intensification of glaucoma treatment) and time from treatment change to subsequent treatment intensification. Results Study eyes (n=6587) underwent treatment intensification 0-to-1 glaucoma drop (5358 events), 1-to-2 drops (1469 events) and 2-to-3 drops (857 events) during the observation period. Median time to treatment failure was 1.60 (95% CI 1.57 to 1.65), 1.00 (95% CI 0.94 to 1.07) and 0.92 (95% CI 0.81 to 1.02) years following escalation 0-to-1, 1-to-2 and 2-to-3 drops, respectively. Median time to treatment intensification (non-IOP–based criterion) was 4.68 (95% CI 4.50 to 5.08) years for treatment initiators, 3.83 (95% CI 3.36 to 4.08) years on escalation 1-to-2 drops and 4.35 (95% CI 3.82 to 4.88) years on escalation 2-to-3 drops. On multivariable regression, significant risk factors for both treatment failure and intensification were lower baseline visual field mean deviation, primary open-angle glaucoma and lower eyedrop count in the fellow eye; lower baseline IOP was associated with treatment failure, higher baseline IOP with treatment intensification. Conclusion Large-scale survival analyses provide the expected duration of treatment success from topical glaucoma medication. Data are available upon reasonable request. The curated anonymised dataset on deidentified participants will be available to researchers on application for data access and after sufficient regulatory approval is obtained and data transfer agreement is signed.

中文翻译：

---

原发性开角型青光眼和高眼压症药物治疗成功的生存率

背景/目的 降低眼内压 (IOP) 的局部药物是预防青光眼的最常见的初始治疗措施。本研究旨在评估开始或加强局部青光眼药物治疗的患者的治疗成功持续时间。方法 从英国五个二级护理和三级护理眼科中心提取成人开始/强化局部青光眼药物治疗的医疗记录（2013-2018 年）。主要研究结果是从治疗开始/强化到治疗失败的时间（连续就诊时眼压降低<20%或眼压>21 mm Hg，或青光眼治疗强化）以及从治疗改变到随后强化治疗的时间。结果 研究眼睛 (n=6587) 在观察期间接受了青光眼强化治疗：0 至 1 滴（5358 起事件）、1 至 2 滴（1469 起事件）和 2 至 3 滴（857 起事件）。 0至1、1至2和升级后，治疗失败的中位时间分别为1.60（95% CI 1.57至1.65）、1.00（95% CI 0.94至1.07）和0.92（95% CI 0.81至1.02）年分别2至3滴。治疗强化的中位时间（非基于 IOP 的标准）为 4.68 年（95% CI 4.50 至 5.08）年，治疗起始者为 3.83 年（95% CI 3.36 至 4.08）年，升级 1 至 2 滴为 4.35 年（95% CI 3.36 至 4.08）年。 % CI 3.82 至 4.88) 年升级 2 至 3 次下降。在多变量回归中，治疗失败和强化治疗的显着危险因素是基线视野平均偏差较低、原发性开角型青光眼和对侧眼眼药水计数较低；较低的基线眼压与治疗失败相关，较高的基线眼压与治疗强化相关。结论 大规模生存分析提供了局部青光眼药物治疗成功的预期持续时间。数据可根据合理要求提供。在申请数据访问、获得足够的监管批准并签署数据传输协议后，研究人员将可以使用有关未识别身份的参与者的精选匿名数据集。